Medscape6d
FDA Approves Inavolisib for HR+, HER2−, Advanced Breast Cancer With PIK3CA Mutation
The FDA also approved the FoundationOne Liquid CDx assay to identify patients who qualify for the newly approved treatment.
FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
Medpage Today on MSN6d
PI3K Inhibitor Wins FDA Approval for Advanced Breast Cancer
The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and ...
Managed Healthcare Executive5d
FDA Approves Itovebi for Metastatic Breast Cancer
Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...
BioWorld5d
FDA gives early nod to Genentech’s first-line breast cancer drug
Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its ...
The Pharma Letter6d
FDA approves Genentech’s Itovebi for PIK3CA-mutated mBC
The Food and Drug Administration (FDA) approved Genentech's Itovebi (inavolisib), in combination with palbociclib (Ibrance) ...
FDA approves Genentech drug aimed at subset of breast cancer patients
The potential blockbuster drug was approved by the agency more than a month before its scheduled decision date. A potential ...
FDA Approves Genentech's Itovebi For Advanced Breast Cancer With PIK3CA Mutation
Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration approved Itovebi (inavolisib), in ...
MedPage Today7d
PI3K Inhibitor Wins FDA Approval for Advanced Breast Cancer
Opens in a new tab or window The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi ... said in a statement from drugmaker Genentech. "The Itovebi-based regimen more than doubled ...
Business Wire6d
FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Itovebiâ„¢ (inavolisib), in ...